Status:
COMPLETED
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
Lead Sponsor:
Almirall, S.A.
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This is an ethics-approved, multi-national, multi-site Phase IV, 1-cohort prospective observational study. The main purpose of this study is to assess the effect of tildrakizumab on the overall wellbe...
Eligibility Criteria
Inclusion
- Patient with diagnosis of moderate-to-severe chronic plaque psoriasis documented in the medical chart.
- Patient who need systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-IL-23p19 selected therapy before including the patient in the study.
- Patient aged 18 years or older at the time of patient recruitment.
- Patient who have provided written informed consent (if required by country regulations).
Exclusion
- Patients unable to comply with the requirements of the study (fulfilling of the study questionnaires) or who, in the opinion of the study physician, should not participate in the study.
- Patients included in a clinical trial.
Key Trial Info
Start Date :
November 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 9 2025
Estimated Enrollment :
782 Patients enrolled
Trial Details
Trial ID
NCT04823247
Start Date
November 22 2021
End Date
January 9 2025
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haut- und Laserzentrum Freising
Freising, Bavaria, Germany, 85354